BR112016019484A2 - peptídeos e métodos de uso - Google Patents

peptídeos e métodos de uso

Info

Publication number
BR112016019484A2
BR112016019484A2 BR112016019484A BR112016019484A BR112016019484A2 BR 112016019484 A2 BR112016019484 A2 BR 112016019484A2 BR 112016019484 A BR112016019484 A BR 112016019484A BR 112016019484 A BR112016019484 A BR 112016019484A BR 112016019484 A2 BR112016019484 A2 BR 112016019484A2
Authority
BR
Brazil
Prior art keywords
peptides
individual
protein
methods
increase
Prior art date
Application number
BR112016019484A
Other languages
English (en)
Inventor
Hartlieb Bettina
Osterkamp Frank
Scheiflinger Friedrich
Paschke Matthias
Dockal Michael
Hartmann Rudolf
Polakowski Thomas
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of BR112016019484A2 publication Critical patent/BR112016019484A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

a invenção refere-se a peptídeos, incluindo peptídeos que ligam e, opcionalmente, inibem a proteína s, e suas composições. os peptídeos podem ser usados para, por exemplo, inibir a atividade de proteína s, aumentar a formação de trombina em um indivíduo, aumentar a formação de coágulo de sangue em um indivíduo, tratar uma desordem de coagulação do sangue em um indivíduo, purificar proteína s, e identificar um composto que liga uma proteína s.
BR112016019484A 2014-02-28 2015-02-27 peptídeos e métodos de uso BR112016019484A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461946103P 2014-02-28 2014-02-28
PCT/US2015/018041 WO2015131061A1 (en) 2014-02-28 2015-02-27 Peptides and methods of use

Publications (1)

Publication Number Publication Date
BR112016019484A2 true BR112016019484A2 (pt) 2017-10-24

Family

ID=52633723

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016019484A BR112016019484A2 (pt) 2014-02-28 2015-02-27 peptídeos e métodos de uso

Country Status (16)

Country Link
US (2) US9447147B2 (pt)
EP (1) EP3110841B1 (pt)
JP (1) JP6711761B2 (pt)
KR (1) KR20160126075A (pt)
CN (1) CN106232615B (pt)
AU (1) AU2015222846B2 (pt)
BR (1) BR112016019484A2 (pt)
CA (1) CA2939658C (pt)
EA (1) EA201691749A1 (pt)
ES (1) ES2873956T3 (pt)
IL (1) IL247448B (pt)
MX (1) MX2016011174A (pt)
PH (1) PH12016501608A1 (pt)
SG (2) SG10201807066UA (pt)
WO (1) WO2015131061A1 (pt)
ZA (1) ZA201605518B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524807A (ja) * 2020-05-05 2023-06-13 ベガ・セラピューティクス・インコーポレイテッド プロテインｓ抗体、その作製方法および使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321123A (en) * 1991-07-02 1994-06-14 The Scripps Research Institute Protein S polypeptides and anti-peptide antibodies that inhibit protein S binding to C4B binding protein, diagnostic systems and therapeutic methods
SE9604378D0 (sv) * 1996-11-27 1996-11-27 Tac Ab Methods and reagents for determining protein S
WO2003039587A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors
EP2547355B1 (en) 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
US9073990B2 (en) 2010-04-05 2015-07-07 Bar-Llan University Protease-activatable pore-forming polypeptides
NZ629130A (en) 2012-03-21 2016-10-28 Baxalta Inc Tfpi inhibitors and methods of use
CN104211799B (zh) * 2013-05-29 2017-12-26 成都渊源生物科技有限公司 人源egf结构域蛋白及其应用

Also Published As

Publication number Publication date
WO2015131061A1 (en) 2015-09-03
IL247448B (en) 2022-09-01
US10124033B2 (en) 2018-11-13
EP3110841B1 (en) 2021-03-31
JP2017509602A (ja) 2017-04-06
EP3110841A1 (en) 2017-01-04
SG10201807066UA (en) 2018-09-27
CN106232615B (zh) 2021-06-01
EA201691749A1 (ru) 2016-12-30
ES2873956T3 (es) 2021-11-04
CN106232615A (zh) 2016-12-14
ZA201605518B (en) 2018-12-19
AU2015222846A1 (en) 2016-08-25
SG11201607067TA (en) 2016-10-28
MX2016011174A (es) 2016-11-15
IL247448A0 (en) 2016-11-30
US20170035835A1 (en) 2017-02-09
KR20160126075A (ko) 2016-11-01
JP6711761B2 (ja) 2020-06-17
PH12016501608A1 (en) 2016-10-03
CA2939658A1 (en) 2015-09-03
AU2015222846B2 (en) 2019-09-19
US20150246947A1 (en) 2015-09-03
CA2939658C (en) 2022-10-04
US9447147B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
EA201791093A1 (ru) Антитела к cd47, способы и применение
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201691582A1 (ru) Новые фармацевтические препараты
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112018009312A2 (pt) método para promover eficiência de purificação de polipeptídeo contendo região de fc
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201690992A1 (ru) Антитела, специфичные к fcrn
BR112015012708A2 (pt) anticorpos para bmp-6
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
BR112018015090A2 (pt) anticorpo anti-trombina, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
BR112019010034A2 (pt) fator viii alvejado de hemácia e método de uso do mesmo
BR112017020610A2 (pt) Compostos de anticorpo biespecífico anti-dkk-1- anti-rankl
BR112017018468A2 (pt) fator de von willebrand modificado com meia-vida aumentada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]